(Reuters) - Eli Lilly and Co (N:LLY) reported a 6.4% rise in second-quarter profit on Thursday, helped by demand for its diabetes drug, Trulicity.
Net income rose to $1.41 billion, or $1.55 per share, in the quarter ended June 30, from $1.33 billion, or $1.44 per share, a year earlier.
Lilly said profit was also boosted by its investments in securities, including two U.S.-based companies that had successful initial public offerings in the second quarter of 2020.